BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TWO SIGMA ADVISERS, LP | 2,519,814 | $202,643,000 | 0.58% |
| HOME FEDERAL BANK OF TENNESSEE | 16,195 | $1,302,000 | 0.57% |
| Pensionfund Sabic | 27,000 | $2,171,000 | 0.55% |
| Handelsbanken Fonder AB | 914,820 | $73,570,000 | 0.54% |
| Bellevue Group AG | 474,623 | $38,169,000 | 0.53% |
| Optimal Asset Management, Inc. | 44,390 | $3,570,000 | 0.52% |
| PEOPLES FINANCIAL SERVICES CORP. | 12,755 | $1,026,000 | 0.52% |
| Stillwater Investment Management, LLC | 17,615 | $1,417,000 | 0.51% |
| COLONY GROUP LLC | 244,060 | $19,627,000 | 0.51% |
| Bayesian Capital Management, LP | 25,700 | $2,067,000 | 0.50% |
| JACOBS & CO/CA | 42,624 | $3,427,000 | 0.50% |
| Pensionfund DSM Netherlands | 34,000 | $2,734,000 | 0.49% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 153,977 | $12,383,000 | 0.49% |
| LAZARD ASSET MANAGEMENT LLC | 4,320,117 | $347,423,000 | 0.49% |
| Point72 Hong Kong Ltd | 57,062 | $4,589,000 | 0.49% |
| MCKINLEY CAPITAL MANAGEMENT LLC | 77,280 | $6,215,000 | 0.48% |
| FIRST NATIONAL TRUST CO | 77,046 | $6,196,000 | 0.48% |
| SEGALL BRYANT & HAMILL, LLC | 441,298 | $35,425,000 | 0.48% |
| WELLINGTON MANAGEMENT GROUP LLP | 28,745,014 | $2,311,674,000 | 0.48% |
| Trexquant Investment LP | 91,975 | $7,397,000 | 0.48% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.